In addition, it is possible that the relationships between tau, neuroinflammation and cognitive progression are not constant, and that the PET biomarkers would have different prognostic relevance during pre-symptomatic, prodromal and dementia stages of Alzheimer’s disease. The gene discussed is MAPT; the disease is Alzheimer disease.